Skip to main content
Figure 6 | Molecular Neurodegeneration

Figure 6

From: The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Figure 6

Everolimus decreases soluble mutant huntingtin levels in muscle, but not brain. Relative quantification of soluble mutant huntingtin by time-resolved FRET. There is no effect of everolimus on soluble mutant huntingtin levels in striatum and cortex (A). Everolimus significantly decreases mean soluble mutant huntingtin in quadriceps muscle (B). X-axes = dose (╬╝moles/kg). ** = p < 0.01, n = 12

Back to article page